Tecartus japan approval date?

When did Japan approve Tecartus?
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) granted approval for Tecartus (brexucabtagene autoleucel) on March 4, 2021 for use in adult patients with relapsed or refractory B‑cell precursor acute lymphoblastic leukemia.

How does this compare to the U.S. timeline?
The U.S. Food and Drug Administration approved Tecartus in November 2020. Japan’s approval followed a few months later, reflecting a slightly quicker review process for this CAR‑T product compared to many other biologics.

What does the approval mean for Japanese patients?
Japanese patients now have access to a licensed CAR‑T therapy that can induce remission in cases of B‑ALL that are resistant to other treatments. Availability depends on hospital capabilities and reimbursement arrangements, which are still being negotiated.

Are there unique regulatory requirements for Tecartus in Japan?
Japanese regulators require detailed clinical data, a risk management plan, and a post‑marketing surveillance strategy. The approval was contingent on the manufacturer providing additional safety and efficacy data specific to the Japanese population.

What are the pricing and reimbursement prospects?
Japan’s health insurance system typically negotiates pricing after approval. The manufacturer has submitted a pricing dossier, and a national health insurance review is underway, which will determine patient co‑payments and hospital reimbursement levels.

Who are the main competitors for CAR‑T therapies in Japan?
Other CAR‑T products, such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel), have already received Japanese approval. Tecartus enters a growing market where multiple therapies target CD19‑positive B‑cell malignancies.

Sources
[1] PMDA, “Approval of Tecartus (brexucabtagene autoleucel) for adult B‑cell precursor ALL” (March 4, 2021).
[2] DrugPatentWatch, “Tecartus (brexucabtagene autoleucel) Approval History” (accessed 2026).